<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Biodesix Looks to Become ‘the’ Lung Cancer Detection Co. With New Acquisition

Biodesix, Boulder, Colo- based company is extending its blood-based lung cancer diagnostic portfolio with the acquisition of Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.

Click to read more.

About Biodesix:

Biodesix is a lung cancer diagnostic company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with non-small cell lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ nodule test, which will be commercially available in the second half of 2019, evaluates the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world’s leading biotechnology and pharmaceutical companies to develop companion diagnostics. For more information about Biodesix, please visit www.biodesix.com.

Topics: In the News